In 2024, we saw another proactive year for some of the biggest names in medtech as they looked to bolster their ranks through acquisitions. Over the course of the year, the number of billion-dollar sales deals continued to climb, with some companies involved more than once. Analysts even suggested that, in 2025, there could be […]
Axonics
Boston Scientific finalizes $3.7B acquisition of Axonics
Boston Scientific (NYSE: BSX) today announced the completion of its $3.7 billion acquisition of Axonics, Inc. (Nasdaq: AXNX). The Marlborough, Massachusetts–based medtech giant priced the deal at $71 per share in cash, representing an equity value of $3.7 billion and an enterprise value of $3.3 billion. The acquisition expands Boston Scientific’s urology offerings by adding […]
The top 10 neurotech stories of the year so far
Across medtech, companies have continued to innovate through the first nine months of 2024, and that rings especially true in the neurotech space. Regulatory achievements, mergers and acquisitions, significant fundraising and more within neurotech have all been topics that garnered the interest of the MassDevice readers so far this year. We even have lists of some […]
Axonics wins regulatory nod in Australia for latest sacral neuromod system
Axonics (Nasdaq:AXNX) announced today that it received regulatory approval in Australia for its R20 rechargeable sacral neuromodulation (SNM) system. The implantable system provides therapy for patients suffering from overactive bladder or fecal incontinence. The R20 neurostimulator uses the same small 5cc form factor as the previous-generation R15. It pairs with the same tined lead and […]
The top 10 urology device stories of 2024 so far
Urology Week 2024, which closes out The Urology Foundation’s Urology Awareness Month, is a good time to highlight the innovations in this space. This week (Sept. 23-29), is an initiative of the European Association of Urology that brings together national urological societies, urology practitioners, urology nurses, patients and their families, and politicians to create awareness of urological […]
Jury says Axonics didn’t infringe on Medtronic patents
Axonics (Nasdaq:AXNX) announced today that a jury unanimously ruled in its favor in a patent spat with Medtronic . The unanimous verdict came down in a patent infringement lawsuit brought by Medtronic against Axonics in U.S. District Court for the Central District of California. The jury found that Axonics does not infringe on any of the […]
FTC wants more info on Boston Scientific, Axonics deal with closing timeline pushed back
Boston Scientific said today that the FTC requested additional information regarding its planned $3.7 billion acquisition of Axonics (Nasdaq:AXNX). In an SEC filing, Boston Scientific said both it and Axonics received requests from the FTC (U.S. Federal Trade Commission). The agency seeks to gather more information in connection with its review of the merger. Reports […]
Axonics stockholders approve Boston Scientific acquisition
Axonics (Nasdaq:AXNX) announced that its stockholders voted to adopt its $3.7 billion merger agreement with Boston Scientific . Boston Scientific announced its intent to buy Axonics on Jan. 8. Irvine, California-based Axonics develops neuromodulation systems for treating urinary and bowel dysfunction. Its fourth-generation R20 rechargeable sacral neuromodulation (SNM) system received FDA approval around a year ago. […]
PTAB upholds two Medtronic patents in spat with Axonics, could go to jury trial
Medtronic announced today that the U.S. Patent and Trademark Office upheld many of its claims around two of its patents in its battle with Axonics (Nasdaq:AXNX). The office’s Patent Trial and Appeal Board (PTAB) affirmed the validity of many of the claims in two of Medtronic’s patents in the latest development in a long-running spat […]
Axonics wins CE mark for 4th-gen rechargeable sacral neuromod system
Axonics (Nasdaq:AXNX) announced today that it received CE mark approval for its R20 rechargeable sacral neuromodulation (SNM) system. The implantable system provides therapy for patients suffering from overactive bladder or fecal incontinence. Axonics won FDA approval for this generation of the R20 in January 2023. The R20 neurostimulator uses the same small 5cc form factor […]
FTC reportedly may scrutinize Boston Scientific’s Axonics deal
Bloomberg reports that the U.S. Federal Trade Commission (FTC) may look into the $3.7 billion acquisition of Axonics (Nasdaq:AXNX) by Boston Scientific . A new Axonics regulatory filing with the SEC discloses that the companies refiled their Hart Scott Rodino (HSR) Act notification to the FTC on March 4 — a move that companies sometimes […]
